trikafta launch premium price
drive next stage growth new po
earli approv trikafta defin point vertex stori
believ robust efficaci abil treat cystic fibrosi
cf patient popul could give trikafta clear path peak potenti though
note earlier expect approv possibl recent
reinstat coverag note think speed approv month
nevertheless impress valid profil among patient prescrib payer
us like ou geographi base discuss manag even
earli launch vertex appear readi meet demand ampl drug product
hand exist sale forc commerci capac new patient servic
team place help acceler access
investor concern launch think like trikafta uptak could
rapid quickli flatten us could provid challeng
growth profil especi pipelin yet contribut end view
kalydeco launch good proxi unpreced cf demand play
commerci inde took quarter reach full penetr elig patient
us doubl digit growth still observ next year
anticip similar trajectori trikafta rapid penetr
still doubl digit growth ou region note ou
geographi provid good cadenc global roll-out begin
expect robust launch reiter buy rate rais po
base increas npv valu trikafta vertex us list
ad trikafta revenu oper model result
non-gaap ep estim total revenu
guidanc net price assumpt increas annual
previous reflect discount gross price rais
trikafta forecast overal rais previous
prior consensu sg estim reflect
higher launch relat expens also rais peak ex-u trikafta penetr
non-gaap ep rais estim
previous prior consensu help support differenti
growth profil revenu non-gaap ep
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
vertex biopharmaceut compani focus
discoveri develop market new
therapi treatment cystic fibrosi
rate vertex buy differenti growth
profil compar peer compani potenti
upsid upcom trikafta launch
price object vertex base npv analysi
forecast sale approv product kalydeco orkambi symdeko
trikafta assum wacc line peer compani
similar size risk vari termin valu asset base
characterist patent life given assumpt estim valu
kalydeco orkambi symdeko trikafta
net cash pipelin
risk price object payer pushback price difficulti secur
reimburs agreement particularli eu clinic trial failur new
competitor cystic fibrosi
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
